Toggle Main Menu Toggle Search

Open Access padlockePrints

Human Proximal Tubular Epithelium Actively Secretes but Does Not Retain Rosuvastatin

Lookup NU author(s): Dr Rachel Sayer, Dr Colin Brown


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Rosuvastatin is a potent HMG-CoA reductase inhibitor that has proven to be effective in the treatment of dyslipidemia. Rosuvastatin is cleared from the body by both biliary and renal clearance, the latter believed to be due to active tubular secretion. Whereas the mechanisms of hepatic clearance of rosu-vastatin are well documented, those of renal clearance are not. Because rosuvastatin (and other statins) may alter proximal tubular function, this study aimed to characterize the mechanisms of tubular rosuvastatin secretion to define the factors that could influence the presence/concentration of rosuvastatin in proximal tubular cells. Hereto, polarized monolayers of primary human tubular cells were used. We found rosuvastatin net secretion across proximal tubule cells, which was saturable (K50 = 20.4 ± 4.1 μM). The basolateral uptake step was rate-limiting and mediated by OAT3. Rosuvastatin efflux at the apical membrane was mediated by MRP2/4 and ABCG2 together with a small contribution from MDR1 or P-glycoprotein. These data, obtained in an intact human tubule cell model, provide a detailed insight into rosuvastatin's renal handling and the possible factors influencing it. Copyright © 2008 The American Society for Pharmacology and Experimental Therapeutics.

Publication metadata

Author(s): Verhulst A, Sayer R, De Broe ME, D'Haese PC, Brown CDA

Publication type: Article

Publication status: Published

Journal: Molecular Pharmacology

Year: 2008

Volume: 74

Issue: 4

Pages: 1084-1091

ISSN (print): 0026-895X

ISSN (electronic): 1521-0111

Publisher: American Society for Pharmacology and Experimental Therapeutics


DOI: 10.1124/mol.108.047647


Altmetrics provided by Altmetric


Funder referenceFunder name
Fund for Scientific Research Flanders
Bijzonder Onderzoeksfonds, University of Antwerp
RP/41/1/2005AstraZeneca (CDAB/MdeB)